Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation - CABANA Pilot Study


The recently published ThermoCool AF study demonstrated the superiority of catheter ablation with pulmonary vein isolation (PVI) over antiarrhythmic drugs (AAD) in the management of patients with symptomatic atrial fibrillation (AF), who had failed at least one AAD. The CABANA pivotal trial tested the hypothesis that primary catheter ablation for the elimination of AF is superior to state-of-the-art drug therapy for reducing recurrent AF in high-risk patients.